Here are three things to know about the study:
- After a drug proved ineffective at inhibiting a lipoprotein that’s associated with an increased risk of cardiovascular disease, researchers at the University of Oxford (U.K.) and the Chinese Academy of Medical Sciences (Beijing) teamed up to see if this outcome could have been predicted using a genetic variant that mimics the drug.
- Researchers explored the relationship between the genetic variant and cardiovascular diseases using data from over 90,000 participants in a prospective China Kadoorie Biobank study. They found that people with non-functioning genetic variants did not have a lower chance of developing cardiovascular diseases, results that matched that of the drug inhibitor study.
- The study’s findings verify the method of using large-scale prospective studies to analyze the linkage between biological pathways associated with diseases prior to conducting expensive, large scale drug trials.
More articles on supply chain:
Novartis clashes with Colombia over high drug costs
Study finds FDA’s 2011 drug safety warning backfired
FDA shoots down KemPharm’s painkiller
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
